Company intelligence / Profile preview
Gracell Biotechnologies
Suzhou, Jiangsu, Chinagracellbio.com ↗
- Ownership
- Public · GRCL
- Employees
- ~314
- Development stage
- Phase 1
01
Overview
Gracell has demonstrated promising early clinical results with its lead asset GC012F, a FasTCAR-enabled autologous dual-targeting BCMA/CD19 CAR-T therapy. This candidate has shown deep and durable responses in patients with relapsed/refractory multiple myeloma and SLE. The company’s next-day manufacturing process aims to improve T-cell quality and reduce time-to-treatment compared to conventional CAR-T approaches. Additional candidates are advancing through preclinical or early clinical development targeting both cancers and autoimmune conditions.
- Therapeutic areas
- HematologyImmunologyOncology
- Modalities
- Autologous CAR-T cell therapies (FasTCAR platform)Allogeneic CAR-T cell therapies (TruUCAR platform)CRISPR-Cas9 genome editing
- Industry
- Biotech
02
Drug pipeline
19 assets18 more assets in the full pipeline.
Beyond the preview
Go deeper on Gracell Biotechnologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gracell Biotechnologies.